Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 23, 2019 (7 years ago)

Cefdinir for Oral Suspension USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Complaint received of metal piece identified in the product bottle prior to the reconstitution.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Cefdinir for Oral Suspension USP, 250mg/5mL, Powder for oral suspension, 60 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 20201, Manufactured by: Lupin Limited, Mandideep 462 046 India. NDC 68180-723-20

Affected NDC 68180-0723-20

Compare with the code on your package — it is the most precise check available.

Drug: Cefdinir

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Cefdinir
NDC 68180-0723
250 mg/5mL Powder, for Suspension
Oral
Lupin Pharmaceuticals, Inc. Rx
Recalling firm
Lupin Pharmaceuticals Inc.
NDC code
68180-723-20
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1320-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cefdinir recalls

See all

Other recalls by Lupin Pharmaceuticals Inc.

All 2019 recalls